A device may record heart rate. An app may chart a trend. A service may ask symptoms. A clinician may use history, examination, and testing to reach a diagnosis. These activities can involve similar information without being interchangeable.
The words matter because they shape expectations, product regulation, and what a person may do next. A wellness tool that quietly behaves like a disease alert system creates a mismatch between its label and its function.
Wellness observation
A general-wellness tool may help a person organize activity, sleep, nutrition, stress-management practices, or other information associated with maintaining a healthy lifestyle. The FDA’s 2026 general-wellness guidance describes a low-risk category while distinguishing it from functions intended for diagnosis, screening, monitoring, alerting, or disease management.[1]
A personal trend can still be useful. Its role should be described accurately: observation and communication support, not a clinical conclusion.
Screening and monitoring
Screening generally looks for a possible condition or concern in people who may not have a known diagnosis. Monitoring follows a known condition, physiological parameter, treatment, or risk-relevant state over time. The exact regulatory meaning depends on the product’s claims, users, data, output, and intended use.
An alert can raise the stakes further because it may prompt or delay action. Sensitivity, specificity, false alarms, missed events, timing, escalation, and user comprehension become central to evaluation.
Diagnosis
Diagnosis is not simply the moment an algorithm produces a label. It is a clinical determination that may integrate symptoms, history, examination, validated testing, alternative explanations, and professional judgment. A consumer wearable classification may provide information for that process without completing it.
The same distinction applies when an output looks polished or uses medical language. Presentation quality does not establish clinical validity.
Why intended use controls the claim
Responsible product communication says what the tool does, who it is for, what evidence supports it, what it does not do, and when a user should seek professional or emergency help. The interface, onboarding, marketing, and evaluation plan should tell the same story.
For SuperstarIQ, the public position is consumer-directed general-wellness planning, information organization, and communication support in development and validation. The Source-Linked Evidence Summary should preserve sources and context; it should not be presented as screening, diagnosis, prediction, prevention, or clearance.
The RTH takeaway
Do not ask only what data a health technology collects. Ask what decision the output is intended to influence. That answer helps distinguish wellness observation from screening, monitoring, alerting, and diagnosis—and determines what evidence and safeguards are needed.
Educational note
This article provides general education and does not provide medical advice, diagnosis, or treatment. Call 911 for a medical emergency and consult a qualified professional about personal symptoms, diagnoses, medication, or care decisions.
Explore more
SuperstarIQ | Medical Disclaimer
Sources and further reading
- U.S. Food and Drug Administration. General Wellness Policy for Low Risk Devices. 2026.
- U.S. Food and Drug Administration. Device Software Functions Including Mobile Medical Applications. accessed 2026.
Published September 15, 2026 · Last reviewed September 15, 2026